Ivermectin B1a
Based on 1 publication(s) in Google Scholar
Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310). Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.97%
- CAS No.: 71827-03-7
- Formule: C48H74O14
- Masse moléculaire:875.09
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antiparasitic Compound library
HY-L082
-
Off-patent Drug Library
HY-L141
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Ivermectin B1a
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
10.42 μM
Compound: 2a; Fig 11, Cpd 2, MK933
|
Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis
Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis
|
[PMID: 34242031] |
| Huh-7 | IC50 |
2.1 μM
Compound: 2a; Fig 11, Cpd 2, MK933
|
Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay
Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay
|
[PMID: 34242031] |
| Huh-7 | IC50 |
2.1 μM
Compound: 2a; Fig 11, Cpd 2, MK933
|
Antiplasmodial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition of parasite infection incubated for 48 hrs by bioluminescence assay
Antiplasmodial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition of parasite infection incubated for 48 hrs by bioluminescence assay
|
[PMID: 34242031] |
Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 μg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 71827-03-7
-
Appearance Solid
-
Masse moléculaire 875.09
-
Formule C48H74O14
-
Color White to light yellow
-
SMILES
C/C([C@H]([C@H](/C=C/C=C1CO[C@]([H])([C@@H](C(C)=C[C@]2(C3=O)[H])O)[C@@]\12O)C)O[C@]4(C[C@@H]([C@H]([C@@H](O4)C)O[C@@]5(O[C@H]([C@@H]([C@H](C5)OC)O)C)[H])OC)[H])=C\C[C@@]6(C[C@@]([H])(C[C@@]7(O6)CC[C@@H]([C@]([H])(O7)[C@@H](C)CC)C)O3)[H]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Solvant et solubilité
DMSO : 100 mg/mL (114.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo). 2017 May;70(5):680-684. [Content Brief]
[2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1427 mL | 5.7137 mL | 11.4274 mL | 28.5685 mL |
| 5 mM | 0.2285 mL | 1.1427 mL | 2.2855 mL | 5.7137 mL | |
| 10 mM | 0.1143 mL | 0.5714 mL | 1.1427 mL | 2.8568 mL | |
| 15 mM | 0.0762 mL | 0.3809 mL | 0.7618 mL | 1.9046 mL | |
| 20 mM | 0.0571 mL | 0.2857 mL | 0.5714 mL | 1.4284 mL | |
| 25 mM | 0.0457 mL | 0.2285 mL | 0.4571 mL | 1.1427 mL | |
| 30 mM | 0.0381 mL | 0.1905 mL | 0.3809 mL | 0.9523 mL | |
| 40 mM | 0.0286 mL | 0.1428 mL | 0.2857 mL | 0.7142 mL | |
| 50 mM | 0.0229 mL | 0.1143 mL | 0.2285 mL | 0.5714 mL | |
| 60 mM | 0.0190 mL | 0.0952 mL | 0.1905 mL | 0.4761 mL | |
| 80 mM | 0.0143 mL | 0.0714 mL | 0.1428 mL | 0.3571 mL | |
| 100 mM | 0.0114 mL | 0.0571 mL | 0.1143 mL | 0.2857 mL |
Ivermectin B1a Related Classifications
HY-126937 Related Classifications
Powered by Bioz